Cargando…
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
Alterations of the EGFR/ERK and Hippo/YAP pathway have been found in non-small cell lung cancer (NSCLC). Herein, we show that ERK1 and ERK2 have an effect on the Hippo/YAP pathway in human NSCLC cells. Firstly, inhibition of ERK1/2 by siRNA or small-molecular inhibitors decreased the YAP protein lev...
Autores principales: | You, Bin, Yang, Yi-Lin, Xu, Zhidong, Dai, Yuyuan, Liu, Shu, Mao, Jian-Hua, Tetsu, Osamu, Li, Hui, Jablons, David M., You, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414195/ https://www.ncbi.nlm.nih.gov/pubmed/25738359 |
Ejemplares similares
-
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2020) -
A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells
por: Dai, Yuyuan, et al.
Publicado: (2021) -
YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017) -
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
por: Hsu, Ping-Chih, et al.
Publicado: (2016) -
YAP and the Hippo pathway in cholangiocarcinoma
por: Sugihara, Takaaki, et al.
Publicado: (2019)